Further, PERK deletion reprogrammed tumor-myeloid cell-derived suppressor cells (MDSCs) into immunostimulatory cells, augmented CD8+ T-cell response and showed a synergistic response in combination with immunotherapy; suggesting PERK inhibition is a promising therapeutic strategy in cancer. Here, EIF2AK3 is linked to cancer.